Inspiremd Inc (NSPR) 0.70 $NSPR
InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015
PR Newswire - Tue Jan 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that it received CE mark approval for its new CGuard RX rapid exchange system for its MicroNet(TM) covered carotid stent technology. Concurrently, the Company announced positive 6 month follow up data from its CGuard(TM) CARENET (CARotid Embolic protection Study using microNET) trial at the LINC (Leipzig InterveNtional Course) meeting in Leipzig, Germany.
NSPR: 0.70 (-0.05)
InspireMD Announces Notification of NYSE MKT Listing Deficiency
PR Newswire - Wed Jan 21, 3:05PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced the receipt of a notice indicating that InspireMD does not meet certain of the NYSE MKT LLC's (the "NYSE MKT" continued listing standards as set forth in Part 10 of the NYSE MKT Company Guide ("Company Guide" . The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange. The Company's management is reviewing its options to address the deficiency and expects to submit a compliance plan on or before the deadline set by the Exchange.
NSPR: 0.70 (-0.05)
InspireMD to Announce Positive Six Month Results from the CGuardTM CARENET Trial at LINC 2015
PR Newswire - Tue Jan 13, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced that six month follow-up data from its CGuardTM CARENET (CARotid Embolic protection Study using microNET) trial continued to show promising clinical benefits, including exceptional safety and efficacy, and most importantly resolution of ischemic lesions and a reduced incidence of restenosis.
NSPR: 0.70 (-0.05)
InspireMD Pre-Announces a Fourth Quarter 2014 Revenue Increase of 200% Over the Third Quarter of 2014 and Provides Update on Corporate and Commercial Strategies
PR Newswire - Mon Jan 05, 3:30PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in stent embolic protection systems ("EPS" , today announced its revenue and cash position for the 2014 fourth quarter, ended December 31. Total revenues were approximately $900,000, which represented a greater than 200% sequential increase over the reported revenue for the third quarter of 2014. InspireMD is also reporting cash and cash equivalents of approximately $6.3 million, as compared to approximately $5 million reported for the 2014 third quarter, reflecting net proceeds of $7.4 million from the Company's registered direct offering in November 2014.
NSPR: 0.70 (-0.05)
InspireMD Announces Important Clinical Data from MASTER and CARENET Trials
PR Newswire - Mon Dec 15, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced results from two important clinical trials. 30 day results from the MASTER II trial which enrolled 310 of a planned 1114 patients was presented at a major cardiology congress in Israel earlier today. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next generation MGuard drug eluting stent (DES) platform. The Company also announced ipsilateral DW-MRI results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.
NSPR: 0.70 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
InspireMD beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:51PM CST
NSPR: 0.70 (-0.05)
InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014
PR Newswire - Wed Nov 12, 3:11PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in stent embolic protection systems ("EPS" , today announced its financial and operating results for the third quarter, ended September 30, 2014.
NSPR: 0.70 (-0.05)
InspireMD concludes USD8.1m registered direct offering of common shares and warrants
M2 - Mon Nov 10, 8:02AM CST
Cardiac stent company InspireMD (NYSE MKT:NSPR) disclosed on Friday the completion of its direct offering of 6.2m shares of common stock and warrants to purchase up to 3.1m shares of common stock at a price of USD1.30 per share.
NSPR: 0.70 (-0.05)
InspireMD Completes $8.1 Million Registered Direct Offering
PR Newswire - Fri Nov 07, 4:20PM CST
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering of approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock at a price of $1.30 per share. Each purchaser received a warrant to purchase 0.5 of a share of common stock for each share of common stock that it purchased in the offering. The warrants are non-exercisable for six months and have a term of exercise of 42 months from the date of issuance and an exercise price of $1.75.
NSPR: 0.70 (-0.05)
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday, November 12th
PR Newswire - Wed Nov 05, 3:05PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in stent embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2014 on Wednesday, November 12th.
NSPR: 0.70 (-0.05)
InspireMD expects gross proceeds of USD8.0m from direct offering
M2 - Wed Nov 05, 6:17AM CST
Stent platform company InspireMD (NYSE MKT:NSPR) disclosed on Tuesday a definitive agreement to sell about 6.2m common shares and warrants to purchase up to 3.1 million common shares in a registered direct offering.
NSPR: 0.70 (-0.05)
InspireMD Announces Registered Direct Offering for Approximately $8 Million
PR Newswire - Tue Nov 04, 8:27AM CST
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definitive agreement to sell approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock in a registered direct offering. The common stock will be sold at a negotiated purchase price of $1.30 per share, and each purchaser will receive a warrant to purchase 0.5 of a share of common stock for each share of common stock that it purchases in the offering. The warrants shall be non-exercisable for six months and have a term of exercise of 42 months from the date of issuance and an exercise price of $1.75. The Company expects to receive gross proceeds from the offering of approximately $8.0 million, before deducting placement agents' fees and estimated offering expenses.
NSPR: 0.70 (-0.05)
InspireMD, Inc. (NSPR) Surges: Stock Moves 12.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:11AM CDT
InspireMD, Inc. (NSPR) was a big mover last session, as the company saw its shares rise over 12% on the day.
XENT: 23.06 (+0.46), ATEC: 1.34 (unch), NSPR: 0.70 (-0.05), ANGO: 18.78 (+0.18)
InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs
PR Newswire - Tue Oct 14, 6:30AM CDT
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today provided commercial, development and clinical updates on the MGuard Prime coronary EPS product line and positioned the Company to address more efficiently its emerging MGuard and CGuard commercial opportunities.
NSPR: 0.70 (-0.05)
InspireMD Announces Initial Commercial Sales of the CGuard(TM) EPS
PR Newswire - Wed Oct 01, 7:40AM CDT
InspireMD, Inc. ("InspireMD" or the "Company" (NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales of the CGuard(TM) carotid EPS. The Company accelerated the limited market release (LMR) of the CGuard based on strong interest created by the recent positive data reported in the CARENET clinical trial.
NSPR: 0.70 (-0.05)
Market Maker Surveillance Report. APT, SPEX, TKMR, NSPR, ANGI, CBDE, Winning Stocks With Lowest Price Friction For Tuesday, September 30th 2014
M2 - Wed Oct 01, 3:55AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4716 companies with "abnormal" market making, 1613 companies with positive Friction Factors and 3632 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Alpha Pro Tech Ltd (NYSE:APT), Spherix Inc (NASDAQ:SPEX), TEKMIRA PHARMACEUTICALS CORP (NASDAQ:TKMR), InspireMD Inc (OTC:NSPR), Angie's List Inc (NASDAQ:ANGI), (NASDAQ:CBDE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CBDE: 0.90 (+0.06), APT: 2.88 (+0.17), ANGI: 5.02 (+0.12), TKMR: 21.45 (-0.22), NSPR: 0.70 (-0.05), SPEX: 0.98 (-0.01)
InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard(TM) CARENET Trial on September 24th
PR Newswire - Thu Sep 18, 2:35PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , will host a live webinar and Q&A to discuss the positive results of its recent CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) Embolic Protection System (EPS) which were announced at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014. The live webinar and Q&A will take place on Wednesday, September 24 at 8:30 AM ET.
NSPR: 0.70 (-0.05)
InspireMD Announces Positive Results from CGuard(TM) CARENET Trial with 0% MACE reported at 30 Days
PR Newswire - Tue Sep 16, 3:10PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company" , a leader in embolic protection systems ("EPS" , today announced positive results from the CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) EPS. This trial demonstrates that the MicroNet(TM) covered CGuard may offer important clinical benefits for patients undergoing carotid artery stenting (CAS).
NSPR: 0.70 (-0.05)
InspireMD Receives CE Mark Approval for Its New CGuard RX and Announces Positive Six Month Follow-Up CARENET Trial Data at LINC 2015
PR Newswire - Tue Jan 27, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that it received CE mark approval for its new CGuard RX rapid exchange system for its MicroNet(TM) covered carotid stent technology. Concurrently, the Company announced positive 6 month follow up data from its CGuard(TM) CARENET (CARotid Embolic protection Study using microNET) trial at the LINC (Leipzig InterveNtional Course) meeting in Leipzig, Germany. NSPR: 0.70 (-0.05)
InspireMD Announces Notification of NYSE MKT Listing Deficiency
PR Newswire - Wed Jan 21, 3:05PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced the receipt of a notice indicating that InspireMD does not meet certain of the NYSE MKT LLC's (the "NYSE MKT" continued listing standards as set forth in Part 10 of the NYSE MKT Company Guide ("Company Guide" . The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange. The Company's management is reviewing its options to address the deficiency and expects to submit a compliance plan on or before the deadline set by the Exchange. NSPR: 0.70 (-0.05)
InspireMD to Announce Positive Six Month Results from the CGuardTM CARENET Trial at LINC 2015
PR Newswire - Tue Jan 13, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced that six month follow-up data from its CGuardTM CARENET (CARotid Embolic protection Study using microNET) trial continued to show promising clinical benefits, including exceptional safety and efficacy, and most importantly resolution of ischemic lesions and a reduced incidence of restenosis. NSPR: 0.70 (-0.05)
InspireMD Pre-Announces a Fourth Quarter 2014 Revenue Increase of 200% Over the Third Quarter of 2014 and Provides Update on Corporate and Commercial Strategies
PR Newswire - Mon Jan 05, 3:30PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in stent embolic protection systems ("EPS" , today announced its revenue and cash position for the 2014 fourth quarter, ended December 31. Total revenues were approximately $900,000, which represented a greater than 200% sequential increase over the reported revenue for the third quarter of 2014. InspireMD is also reporting cash and cash equivalents of approximately $6.3 million, as compared to approximately $5 million reported for the 2014 third quarter, reflecting net proceeds of $7.4 million from the Company's registered direct offering in November 2014. NSPR: 0.70 (-0.05)
InspireMD Announces Important Clinical Data from MASTER and CARENET Trials
PR Newswire - Mon Dec 15, 7:30AM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced results from two important clinical trials. 30 day results from the MASTER II trial which enrolled 310 of a planned 1114 patients was presented at a major cardiology congress in Israel earlier today. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next generation MGuard drug eluting stent (DES) platform. The Company also announced ipsilateral DW-MRI results from the CARENET Trial for the CGuard system which successfully completed enrollment in July. NSPR: 0.70 (-0.05)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 11:45AM CST
SD: 2.09 (+0.14), FRO: 2.96 (+0.07), ABCO: 53.69 (+0.32), ZAZA: 2.17 (+0.08), JMEI: 12.67 (+0.31), SGMO: 15.40 (+0.14), TGTX: 13.13 (-0.19), MEI: 39.40 (+0.22), WLT: 1.09 (+0.05), NSPR: 0.70 (-0.05), VII: 1.47 (-0.02), CVTI: 29.64 (-0.13), MEIP: 5.00 (-0.04), ALDR: 26.06 (+0.18), CALA: 16.11 (+0.62), CGG: 6.86 (+0.06), SPP: 1.36 (unch), DSCO: 1.43 (+0.05), KPTI: 27.12 (-0.13), HBOS: 24.84 (+0.14)
InspireMD beats by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:51PM CST
NSPR: 0.70 (-0.05)
InspireMD Reports Financial Results for the Third Quarter ended September 30, 2014
PR Newswire - Wed Nov 12, 3:11PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in stent embolic protection systems ("EPS" , today announced its financial and operating results for the third quarter, ended September 30, 2014. NSPR: 0.70 (-0.05)
InspireMD concludes USD8.1m registered direct offering of common shares and warrants
M2 - Mon Nov 10, 8:02AM CST
Cardiac stent company InspireMD (NYSE MKT:NSPR) disclosed on Friday the completion of its direct offering of 6.2m shares of common stock and warrants to purchase up to 3.1m shares of common stock at a price of USD1.30 per share.
NSPR: 0.70 (-0.05)
InspireMD Completes $8.1 Million Registered Direct Offering
PR Newswire - Fri Nov 07, 4:20PM CST
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering of approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock at a price of $1.30 per share. Each purchaser received a warrant to purchase 0.5 of a share of common stock for each share of common stock that it purchased in the offering. The warrants are non-exercisable for six months and have a term of exercise of 42 months from the date of issuance and an exercise price of $1.75. NSPR: 0.70 (-0.05)
InspireMD to Report Financial Results for the Third Quarter Ended September 30, 2014 on Wednesday, November 12th
PR Newswire - Wed Nov 05, 3:05PM CST
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in stent embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2014 on Wednesday, November 12th. NSPR: 0.70 (-0.05)
InspireMD expects gross proceeds of USD8.0m from direct offering
M2 - Wed Nov 05, 6:17AM CST
Stent platform company InspireMD (NYSE MKT:NSPR) disclosed on Tuesday a definitive agreement to sell about 6.2m common shares and warrants to purchase up to 3.1 million common shares in a registered direct offering.
NSPR: 0.70 (-0.05)
InspireMD Announces Registered Direct Offering for Approximately $8 Million
PR Newswire - Tue Nov 04, 8:27AM CST
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced that it has entered into a definitive agreement to sell approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock in a registered direct offering. The common stock will be sold at a negotiated purchase price of $1.30 per share, and each purchaser will receive a warrant to purchase 0.5 of a share of common stock for each share of common stock that it purchases in the offering. The warrants shall be non-exercisable for six months and have a term of exercise of 42 months from the date of issuance and an exercise price of $1.75. The Company expects to receive gross proceeds from the offering of approximately $8.0 million, before deducting placement agents' fees and estimated offering expenses. NSPR: 0.70 (-0.05)
InspireMD, Inc. (NSPR) Surges: Stock Moves 12.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 8:11AM CDT
InspireMD, Inc. (NSPR) was a big mover last session, as the company saw its shares rise over 12% on the day.
XENT: 23.06 (+0.46), ATEC: 1.34 (unch), NSPR: 0.70 (-0.05), ANGO: 18.78 (+0.18)
InspireMD Resumes MGuard Prime Sales and Prioritizes DES and Carotid - New Product Programs
PR Newswire - Tue Oct 14, 6:30AM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today provided commercial, development and clinical updates on the MGuard Prime coronary EPS product line and positioned the Company to address more efficiently its emerging MGuard and CGuard commercial opportunities. NSPR: 0.70 (-0.05)
InspireMD Announces Initial Commercial Sales of the CGuard(TM) EPS
PR Newswire - Wed Oct 01, 7:40AM CDT
InspireMD, Inc. ("InspireMD" or the "Company"
(NYSE MKT: NSPR), a leader in embolic protection systems (EPS), today announced that it has recorded the first commercial sales of the CGuard(TM) carotid EPS. The Company accelerated the limited market release (LMR) of the CGuard based on strong interest created by the recent positive data reported in the CARENET clinical trial. NSPR: 0.70 (-0.05)
Market Maker Surveillance Report. APT, SPEX, TKMR, NSPR, ANGI, CBDE, Winning Stocks With Lowest Price Friction For Tuesday, September 30th 2014
M2 - Wed Oct 01, 3:55AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4716 companies with "abnormal" market making, 1613 companies with positive Friction Factors and 3632 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Alpha Pro Tech Ltd (NYSE:APT), Spherix Inc (NASDAQ:SPEX), TEKMIRA PHARMACEUTICALS CORP (NASDAQ:TKMR), InspireMD Inc (OTC:NSPR), Angie's List Inc (NASDAQ:ANGI), (NASDAQ:CBDE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
CBDE: 0.90 (+0.06), APT: 2.88 (+0.17), ANGI: 5.02 (+0.12), TKMR: 21.45 (-0.22), NSPR: 0.70 (-0.05), SPEX: 0.98 (-0.01)
InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard(TM) CARENET Trial on September 24th
PR Newswire - Thu Sep 18, 2:35PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , will host a live webinar and Q&A to discuss the positive results of its recent CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) Embolic Protection System (EPS) which were announced at the Transcatheter Cardiovascular Therapeutics (TCT) conference, in Washington, D.C. on Tuesday September 16, 2014. The live webinar and Q&A will take place on Wednesday, September 24 at 8:30 AM ET. NSPR: 0.70 (-0.05)
InspireMD Announces Positive Results from CGuard(TM) CARENET Trial with 0% MACE reported at 30 Days
PR Newswire - Tue Sep 16, 3:10PM CDT
InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"
, a leader in embolic protection systems ("EPS" , today announced positive results from the CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard(TM) EPS. This trial demonstrates that the MicroNet(TM) covered CGuard may offer important clinical benefits for patients undergoing carotid artery stenting (CAS). NSPR: 0.70 (-0.05)
